Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

See Which of These Two Surging Biotech Stocks Hedge Funds Approve On

Page 1 of 2

Thursday turns out a bad day for investors as major indices slipped by more than 1% amid pressure from declining global markets and hours before Fed Chair Janet Yellen speech on inflation scheduled after the bell. However, in the crowd of many declining stocks, including Caterpillar Inc. (NYSE:CAT), which slipped by over 7% (see here why), several stocks are registering large upside, although many of them are small- and nano-cap companies that don’t have a large impact on the overall market. In this article we would like to discuss two biotech companies, whose stocks advanced today with large trading volumes.

Biotech Lab Testing

Today’s market activity emphasizes the importance of our research, which focuses on the small-cap space. We analyze the popularity of different stocks among a pool of over 730 hedge funds and our backtests that covered the period between 1999 and 2012 showed that their most popular picks (which are mostly represented by large companies) on average slightly underperform the broader market each month, by around seven basis points to be more specific. On the other hand, their small-cap ideas are less efficiently priced and offer more upside potential, which is why they beat the market by almost one percentage point per month on average. Our strategy involves imitating a portfolio of 15 most popular small-cap picks among hedge funds and it has returned 118% since August 2013, compared to around 59% for the S&P 500 ETF (SPY) (read more details here).

With this in mind, let’s take a closer look at the top gainers in the healthcare today, starting with Arrowhead Research Corp (NASDAQ:ARWR), whose stock opened over 30% in green, but later retracted to around 18%. The boost came on the back of the data released by the company that proved the efficiency of its hepatitis B treatment. Bullish investors have been looking forward to positive results, since the drug might have annual sales of $4.5 billion, taking into account a market entry by 2020, according to Jefferies analysts cited by the Wall Street Journal. Hedge funds from our database are still bullish the stock, taking into account that it has underperformed the biotech industry by around 10 percentage points since the beginning of the year. Between April and June, the number of funds with long positions in Arrowhead Research Corp (NASDAQ:ARWR) slid to nine from 11, while the total value of these stakes dropped to $36.12 million from $63.68 million. Still, at the end of June, hedge funds amassed almost 9% of the company’s outstanding stock in their equity portfolios. The decline of the aggregate value of positions was affected by the most investors’ decisions to limit their exposure to the company. In this way, Israel Englander’s Millennium Management, Daniel Gold‘s QVT Financial, and Julian and Felix Bakers’ Baker Bros. Advisors cut their stakes to 2.14 million shares, 1.60 million shares, and 1.0 million shares, but still ranked as the top three shareholders in our database. On the other hand, billionaires Ken Griffin‘s Citadel Investment Group and Steve Cohen’s Point72 Asset Management disclosed new positions containing 41,700 shares and 22,200 shares of Arrowhead Research in their 13F filings.

Follow Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR)
Trade (NASDAQ:ARWR) Now!
Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!